Navigation Links
Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Date:12/22/2009

CAMBRIDGE, Massachusetts, December 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a BLA with the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease. REPLAGAL first received marketing authorization in the European Union in 2001, and is approved for the treatment of Fabry disease in 45 countries.

REPLAGAL is currently available to U.S. Fabry patients under an FDA-approved treatment protocol, and the Company is also supporting emergency IND requests. Shire worked closely with the FDA to establish an early access program in response to the ongoing shortage of the currently marketed treatment for Fabry disease in the U.S.

"We continue to deliver on our commitment to the Fabry community by filing a BLA to support long-term access to REPLAGAL in the United States," said Sylvie Gregoire, President of Shire Human Genetic Therapies. "We understand that this has been a difficult time for patients and we remain committed to doing all we can to support the Fabry community during the supply shortage and for the long-term."

Shire expects its REPLAGAL supply to be adequate to meet anticipated global demand.

Update on Shire's Potential Gaucher Disease Treatment

In light of the supply restrictions on one of the commercially available products for Gaucher disease during the past six months, Shire has provided the following update on recent key activities regarding global access to velaglucerase alfa, its enzyme replacement therapy in development for Type 1 Gaucher disease:

    - The Company has submitted marketing applications for velaglucerase alfa
      in the U.S., EU and Canada. In the U.S., the application is being
      
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter(TM) Page
2. Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
3. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
4. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
5. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
6. Shire Continues to Deliver Excellent Growth From Core Products
7. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
8. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
9. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
10. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
11. Veriscrip and DAMMAD Team Up to Combat Prescription Drug Abuse in New Hampshire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aspire Technology Partners (Aspire) announced today that it has achieved ... recognizes Aspire for delivering outstanding customer service to customers in ... "Achieving exceptional results for our customers is core to ... CEO of Aspire. "We are pleased Cisco has recognized our ... are proud to be part of the Cisco channel." ...
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
(Date:8/1/2014)... Aug. 1, 2014 Arena Pharmaceuticals, Inc. ... corporate update and reported financial results for the ... "We have continued to see encouraging advancements ... 43% quarter-over-quarter increase in estimated total prescriptions and ... mark," said Jack Lief, Arena,s President and Chief ...
Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
... DALLAS, June 23, 2011 , - ReportsnReports ... and,Combination Therapies , Report in its store ... Combination,Therapies , Report now! Search 75000+ ... , Pharmaceuticals Market Research Reports Report ...
... Inc., a privately held biotechnology company that develops immunotherapeutics ... announced that 1-year data from Protege, the Company,s Phase ... patients, will be presented at the American Diabetes Association,s ... June 28, 2011 at 9:10 a.m. PDT. ...
Cached Medicine Technology:ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies 2ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies 3ReportsnReports - Multitargeted Therapies: Promiscuous Drugs and Combination Therapies 4MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28 2
(Date:8/1/2014)... The American Telemedicine Association (ATA) ... and Peter Welch (D-VT), for their latest actions ... Act of 2014, which improves telemedicine coverage in ... improve healthcare access and affordability using telecommunications technology," ... "These cost-saving provisions are critical to improve telehealth ...
(Date:8/1/2014)... Market Publishers Ltd announces that ... added to its catalogue. , Pharmaceutical ... Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics ... include, among others, increasing ageing population, rising incomes ... the pharma market in India is anticipated to ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
(Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although many parents ... many overlook a common choking hazard: food. Such ... wheeze and cough after eating a handful of nuts. ... not obvious if the coughing was related to his illness ... wasn,t a cold. A cashew had become lodged in his ...
Breaking Medicine News(10 mins):Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:FDA Approves New Treatment for People With COPD 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2
... CryoCor, Inc. (Nasdaq:,CRYO), a medical device company focused ... Jackman, M.D., joined the Company,s,Scientific Advisory Board., ... to our Scientific,Advisory Board," said Dr. Ed Brennan, ... key thought leader in the field of cardiac ...
... 4 IPC The,Hospitalist Company, Inc. (Nasdaq: IPCM ), ... Singer, Chief Executive Officer, and,Jeffrey Taylor, President and Chief Operating ... the UBS Global Healthcare Services,Conference in New York, NY., ... Date: Monday, February 11, 2008 Time: ...
... 2008) The 2008 HSR Impact Award, presented today ... D.C., honored two decades or research that ultimately brought ... , Now in its third year, the AcademyHealth HSR ... of health services research on health policy or practice. ...
... executive team; Jerry Noyce announces ... ... HFIT) announced today that John Griffin has joined the,company as chief ... officer and Jerry Noyce has retired as vice,chairman. HealthFitness is a ...
... and other products reach $3.8 million; revenue increased 18% to $3.75 ... markets - Strong operating leverage shows in sequential quarter comparisons, ... ... quarter fiscal 2008, - Purchase of medical waste disposal facility ...
... Improve Pediatric Emergency Care ... -, ... reducing the high level of infant mortality in,the United States, announced today that ... five new hospital programs that,received grants in January 2008 totaling $500,000. R Baby ...
Cached Medicine News:Health News:Dr. Warren Jackman Joins CryoCor Scientific Advisory Board 2Health News:Dr. Warren Jackman Joins CryoCor Scientific Advisory Board 3Health News:IPC The Hospitalist Company, Inc. to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:Award recognizes 2 decades of research that led to the adoption of risk adjustment tools 2Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 2Health News:HealthFitness Announces Executive Changes: Chief Operations Officer And New Medical Officer Appointed; Vice Chairman Retires 3Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 2Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 3Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 4Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 5Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 6Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 7Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 8Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 9Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 10Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 11Health News:Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008 12Health News:R Baby Foundation Raises $2.5 Million in First Year 2Health News:R Baby Foundation Raises $2.5 Million in First Year 3Health News:R Baby Foundation Raises $2.5 Million in First Year 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: